

Molecular and Cellular Pathobiology

Inflammatory Processes Triggered by *Helicobacter pylori* Infection Cause Aberrant DNA Methylation in Gastric Epithelial Cells

Tohru Niwa¹, Tetsuya Tsukamoto², Takeshi Toyoda², Akiko Mori¹, Harunari Tanaka², Takao Maekita³, Masao Ichinose³, Masae Tatematsu², and Toshikazu Ushijima¹

Abstract

Altered patterns of DNA methylation associated with *Helicobacter pylori* (*HP*) infection of gastric epithelial cells are thought to contribute to gastric cancer risk. However, it is unclear whether this increased risk reflects an infection-associated inflammatory response or the infection itself. In this study, we sought to clarify mechanisms in a gerbil model of gastric cancer where we showed that *HP* infection is causally involved in induction of aberrant DNA methylation. By genome-wide screening, CpG islands that were aberrantly methylated in gerbil gastric cancer cell lines were isolated, and 10 islands were shown to be specifically methylated only in gastric mucosae infected with *HP*. By temporal analysis, methylation levels in gastric epithelial cells started to increase at 5 to 10 weeks after infection and reached high levels by 50 weeks. When *HP* was eradicated, methylation levels markedly decreased 10 and 20 weeks later, but they remained higher than those in gerbils that were not infected by *HP*. Expression levels of several inflammation-related genes (*CXCL2*, *IL-1 β* , *NOS2*, and *TNF- α*) paralleled the temporal changes of methylation levels. Significantly suppressing inflammation with the immunosuppressive drug cyclosporin A did not affect colonization by *HP* but blocked the induction of altered DNA methylation. Our findings argue that DNA methylation alterations that occur in gastric mucosae after *HP* infection are composed of transient components and permanent components, and that it is the infection-associated inflammatory response, rather than *HP* itself, which is responsible for inducing the altered DNA methylation. *Cancer Res*; 70(4); 1430–40. ©2010 AACR.

Introduction

Aberrant DNA methylation of promoter CpG islands (CGI) is one of the major inactivating mechanisms of tumor-suppressor genes and is deeply involved in human carcinogenesis (1). Nevertheless, there is only limited information on its inducers and induction mechanisms. Chronic inflammation, known to promote certain types of cancers (2), is one of the possible inducers of aberrant methylation. The presence of aberrant methylation is frequently observed in non-cancerous tissues of patients with inflammation-associated cancers, such as liver cancers, ulcerative colitis-associated colon cancers, and gastric cancers (3–7). However, a causal role of chronic inflammation in methylation induction remains to be established.

Authors' Affiliations: ¹Carcinogenesis Division, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan; ²Division of Oncological Pathology, Aichi Cancer Center Research Institute, Chikusa, Nagoya, Japan; and ³Second Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan

Note: Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

Corresponding Author: Toshikazu Ushijima, Carcinogenesis Division, National Cancer Center Research Institute, 5-1-1-Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Phone: 81-3-3542-2511; Fax: 81-3-5565-1753; E-mail: tushijim@ncc.go.jp.

doi: 10.1158/0008-5472.CAN-09-2755

©2010 American Association for Cancer Research.

In human gastric mucosae, the presence of *Helicobacter pylori* (*HP*) infection, a well-known inducer of chronic inflammation and gastric cancers (8, 9), is associated with high methylation levels or high incidences of methylation (5, 10–12). In addition, among individuals without *HP* infection, noncancerous gastric mucosae of gastric cancer patients have higher methylation levels than gastric mucosae of healthy individuals (5, 10). In addition, eradication of *HP* leads to a decreased incidence of *CDH1* (*E-cadherin*) promoter methylation (11, 13, 14). These findings suggest that *HP* infection induces aberrant methylation in gastric mucosae and indicate that levels of accumulated methylation are associated with gastric cancer risk. However, because infection experiments are impossible in humans, it needs to be clarified in animal models whether or not *HP* infection induces methylation and what mechanisms are involved.

HP infection in humans is best modeled in Mongolian gerbils (*Meriones unguiculatus*). As in man, *HP* infection induces severe inflammation in gerbil gastric mucosae and promotes gastric carcinogenesis induced by administration of *N*-methyl-*N*-nitrosourea (MNU) or *N*-methyl-*N'*-nitrosoguanidine (15). The incidence of gastric cancers in gerbils depends on the duration of *HP* infection, and eradication of *HP* significantly reduces the incidence (16), as in man (17, 18). Thus, we can expect that the gerbil model is also useful in analyzing whether *HP* infection induces aberrant methylation and what mechanisms are involved *in vivo*. However, unfortunately,

little information is available for the gerbil genome, and the genetic and molecular analysis of this model has been hampered.

In this study, we aimed to show that *HP* infection is causally involved in induction of aberrant DNA methylation and to clarify a critical factor involved. For this, we first isolated CGIs that could be methylated in gerbil gastric cancers by a genome-wide screening method, methylation-sensitive representational difference analysis (MS-RDA). Using the CGIs isolated, we then showed that methylation was induced specifically in gerbils with *HP* infection and that inflammation induced by *HP* infection, not *HP* itself, was critically involved in methylation induction.

Materials and Methods

Cell lines. Two gerbil gastric cancer cell lines, MGC1 and MGC2, were established from a single gastric cancer induced in a gerbil by MNU and *HP* infection (19). They were maintained in RPMI 1640 supplemented with 10% fetal bovine serum on a type I collagen-coated dish (Asahi Techno Glass). Although we did not check the cross-contamination of cell lines biochemically or genetically just before use, they had the same morphology and growth rates as described previously (19).

Animal experiments and sample preparation. Male Mongolian gerbils (MGS/Sea) were purchased from Kyudo. To induce gastric cancers, male gerbils were administered with 30 ppm of MNU (Sigma-Aldrich) in drinking water for a week at 7, 9, 11, 13, and 15 wk of age, and then inoculated with *HP* (ATCC 43504, American Type Culture Collection) by gavage at 17 wk of age (20). At 57 wk, gerbils were sacrificed and stomachs were resected. Because it was difficult to identify cancers macroscopically in gastric mucosae with severe hyperplasia, we dissected an area of gastric cancer tissue by an apparatus for laser microdissection (ASLMD, Leica Microsystems) after histologic confirmation. For temporal analysis of methylation levels, male gerbils were inoculated with *HP* (ATCC 43504) at 5 wk of age. Eradication therapy was done at 55 wk of age by administering amoxicillin, clarithromycin, and lansoprazole by gavage (20). Gerbils that had *HP* after the eradication therapy were excluded from analysis. As a vehicle control, 0.5% of carboxymethyl cellulose was given by gavage. To suppress gastritis, gerbils were administered with 250 µg/mL cyclosporin A (CsA; Neoral, Novartis Pharma) in drinking water for 20 wk. The stomach was resected and cut along the greater curvature. From the posterior wall of the pyloric region (pyloric antrum), which contains the pyloric glands, gastric epithelial cells (GEC) were isolated by the gland isolation technique (21). The anterior wall of the pyloric region was further cut into two pieces: one for RNA and DNA extraction from a sample with mucus and mucosal and submucosal layers and the other for histologic analysis. Whole blood was obtained from the inferior vena cava. The animal experiment protocols were approved by the Committee for Ethics in Animal Experimentation.

Human clinical samples. Human gastric mucosae were obtained by endoscopic biopsy from 10 *HP*-negative (five

men and five women; average age 42.4 y, ranging from 29 to 56 y) and 10 *HP*-positive (four men and six women; average age 42.4 y, ranging from 23 to 53 y) healthy volunteers, whose *HP* status had been judged by a serum anti-*HP* antibody test (SBS). Gastric cancer samples were obtained from surgical specimens from 14 patients who underwent gastrectomy due to early gastric cancers (seven men and seven women; average age 65.9 y, ranging from 47 to 79 y). Sampling was conducted under the approval of Institutional Review Boards.

Nucleic acid extraction. From tissue sections, DNA was extracted by heating the dissected sections at 100°C for 20 min at pH 12, followed by phenol/chloroform extraction (22). From isolated glands, DNA was extracted by proteinase K digestion and the phenol/chloroform method. From the whole blood, DNA was extracted with a QuickGene DNA whole blood kit (Fujifilm). RNA was isolated with Isogen (Wako).

Quantitative PCR for gene expression analyses and HP detection. To analyze gene expression levels, cDNA was synthesized from 2 µg of DNase-treated RNA with an oligo-d(T)₁₂₋₁₈ primer. Real-time PCR using gene-specific primers (Supplementary Table S1) and SYBR Green Real-time PCR Master Mix (TOYOBO) was done, and the amplification curve of a sample was compared with curves of standard DNA samples with known copy numbers. Standard DNA samples were prepared by serial dilution of a PCR product or a plasmid containing a cloned PCR fragment after its quantification. Gene expression levels were normalized to that of *Gapdh*. To measure the amount of *HP*, real-time PCR using specific primers for the *jhpr3* gene of *HP* was carried out and normalized to the gerbil *Il4* gene (Supplementary Table S1).

Methylation-sensitive representational difference analysis. MS-RDA is a subtraction method that can identify differentially methylated loci between two genomes independent of genomic information (23) and was done using *HpaII* or *SacII* methylation-sensitive restriction enzyme as described previously (24). The final PCR product was cloned into pGEM T-Easy (Promega) and sequenced. If a DNA fragment had a CpG score ≥ 0.65 and G + C content $\geq 55\%$, the fragment was considered to be derived from a CGI. To identify homologous regions in mice and men, database searches were carried out at a GenBank web site.

Methylation analysis. Fully methylated and fully unmethylated controls were prepared by methylating genomic DNA with *SssI* methylase (New England Biolabs) and amplifying genomic DNA with $\phi 29$ DNA polymerase (GenomiPhi DNA Amplification Kit, GE Healthcare), respectively (25). One microgram of DNA digested with *BamHI* was treated with sodium bisulfite and suspended in 80 µL of Tris-EDTA (TE) buffer as described previously (22). In the case of paraffin-embedded samples, DNA was treated with sodium bisulfite without *BamHI* digestion and suspended in 20 µL of TE buffer. One microliter of aliquot was used as a template for methylation-specific PCR (MSP) and bisulfite sequencing. Conventional MSP and bisulfite sequencing were done with specific primer sets (Supplementary Table S2) as described previously (22). Quantitative MSP (qMSP) was done

Table 1. CGIs methylated in gerbil gastric cancer cell lines and *HP*-infected GECs

Clone name	GenBank accession no.	Genomic location deduced from analyses using human or mouse genome database	Nucleotide position in human or mouse sequences
HE6	AB429514	Exon 2 of <i>Ntrk2</i> gene*	16,449,514–16,449,840 bp in NT_023935.17 (human chr. 9)
HG2	AB429515	Exon 1 of <i>Gpr37</i> gene*	49,589,571–49,589,704 bp in NT_007933.14 (human chr. 7)
SA9	AB429516	Exon 1 of <i>Nol4</i> gene*	13,292,105–13,292,430 bp in NT_010966.13 (human chr. 18)
SB1	AB429517	Intergenic region between <i>Sp4</i> and <i>Sp8</i> genes*	20,698,454–20,698,697 bp in NT_007819.16 (human chr. 7)
SB5	AB429513	Not identified	Not identified
SC3	AB429518	Promoter region of <i>Rnf152</i> gene*	7,352,575–7,352,875 bp in NT_025028.13 (human chr. 18)
SD2	AB429519	Promoter region of <i>Nptx2</i> gene*	23,480,374–23,480,422 bp in NT_007933.14 (human chr. 7)
SE3	AB429520	Intron 1 of <i>Slc35f1</i> gene*	39,311,942–39,312,270 bp in NT_001838990.2 (human chr. 6)
SF12	AB429521	Intergenic region between <i>Cntn1</i> and <i>Pdzm4</i> genes	53,513,634–53,513,936 bp in NT_039621.7 (mouse chr. 15)
SH6	AB429522	Intergenic region between <i>Sox1</i> and <i>Loc729095</i> gene*	213,253–213,298 bp in NT_027140.6 (human chr. 13)

*Conserved regions identified in the human database.

by real-time PCR using primers specific to DNA molecules methylated at a locus and to a repeat sequence. Methylation levels were expressed as a percentage of the methylated reference, which was obtained as [(number of methylated fragments of a target CGI in sample) / (number of repeat sequences in sample)] / [(number of methylated fragments of a target CGI in *SssI*-treated DNA) / (number of repeat sequences in *SssI*-treated DNA)] × 100. As a repeat sequence, the B2 repeat was used for gerbil DNA (ref. 26; Supplementary Table S2 and Supplementary Fig. S1) and the *Alu* repeat was used for human DNA (27).

Statistical analysis. Statistical analyses were conducted with SPSS 13.0J (SPSS Japan, Inc.). To evaluate significant difference between two independent groups of sample data, the Mann-Whitney *U* test was used. Spearman's rank correlation coefficient (*r*) was used to measure correlation.

Results

Identification of CGIs specifically methylated by *HP* infection in GECs of Mongolian gerbils. To identify CGIs methylated in GECs of gerbils with *HP* infection, we adopted the strategy of a genome-wide screening in cancers and high-sensitivity analysis in GECs. The genome-wide screening was done by MS-RDA using a pool of two gerbil gastric cancer cell lines (MGC1 and MGC2) as the driver and GECs of noninfected gerbils as the tester. The final products of two series of MS-RDA using *HpaII* and *SacII* were cloned and 180 DNA fragments were sequenced. One hundred three of them were

nonredundant, and 56 of them contained a sequence likely to have originated from a CGI. Due to the lack of information on the gerbil genome, we first analyzed the methylation statuses of CpG sites within the DNA fragments isolated using MSP. MSP primers were successfully designed for 27 of the 56 DNA fragments, and we analyzed the two gastric cancer cell lines, five samples of GECs from gerbils infected with *HP* for 50 weeks, and five samples of GECs from age-matched gerbils without infection. Ten (HE6, HG2, SA9, SB1, SB5, SC3, SD2, SE3, SF12, and SH6) of the 27 DNA fragments were methylated in the cell lines and GECs of *HP*-infected gerbils, but not in any GECs of gerbils without infection (Table 1; Fig. 1). The others were methylated only in the cell lines or methylated even in GECs of gerbils without infection.

Methylation in primary gastric cancers was analyzed for three randomly selected CGIs (HE6, SA9, and SB5). The methylation levels of HE6 and SB5 in eight primary cancer samples were similar to or below the mean methylation levels in GECs with *HP* infection for 50 weeks. In contrast, the methylation level of SA9 in most cancer samples was 2.1- to 19.1-fold higher than the mean methylation level in GECs from *HP*-infected gerbils (Supplementary Fig. S2). These results suggested that *HP* infection induced aberrant methylation of multiple but specific CGIs in gerbil GECs, and that methylation of some of these CGIs was associated with growth advantage of the cells.

Methylation of the corresponding CGIs in human samples. To examine whether or not these CGIs are also methylated in humans by *HP* infection, conserved regions of the

10 gerbil CGIs in humans were searched for. Eight of the 10 CGIs were found to be conserved between gerbils and humans (marked in Table 1), and five were located in the vicinities of genes (Fig. 2A, left). When the methylation levels of these five CGIs were quantified in human gastric mucosal biopsies, all of them had 5- to 48-fold higher methylation levels in individuals with *HP* infection ($n = 10$) than in those without ($n = 10$; right). Their methylation levels had close correlation with each other (correlation coefficient = 0.70–0.88; Supplementary Table S3).

The methylation levels of the five CGIs were then analyzed in primary human gastric cancers. *NTRK2*, *GPR37*, *NOLA*, and *NPTX2* had methylation in seven, three, four, and five, respectively, of 14 cancers analyzed, using the average methylation level of mucosal biopsies of *HP*-infected healthy volunteers as a threshold. There was no case with methylation of *RNF152* (Fig. 2B). These results showed that some of these CGIs were also methylated in human gastric cancers.

Induction of DNA methylation by chronic *HP* infection.

Using the 10 CGIs isolated by MS-RDA, the effect of *HP* infection on methylation induction was analyzed at 1, 5, 10,

and 50 weeks after *HP* infection (Fig. 3A). The methylation levels of HG2, SB5, and SD2 started to increase at 5 weeks after infection. At 10 weeks, CGIs other than SE3 and SH6 showed significantly higher methylation levels than those of the noninfected gerbils (3.2- to 85.0-fold). At 50 weeks, all the CGIs showed significantly higher methylation levels (14.3- to 215-fold; Fig. 3B; Supplementary Fig. S3). These results suggested that chronic *HP* infection, not acute *HP* infection, was responsible for methylation induction.

The presence of dense methylation (methylation of a majority of CpG sites on a single DNA molecule) was confirmed by bisulfite sequencing of HE6 and SA9 in GECs of two gerbils with *HP* infection and two without. Densely methylated DNA molecules were detected only in *HP*-infected gerbils (Fig. 3C). The vast majority of DNA molecules were either largely unmethylated or largely methylated, and the fraction of methylated DNA molecules was in accordance with methylation levels measured by qMSP. The methylation levels of the 10 CGIs closely correlated with each other (average correlation coefficient = 0.87; range 0.70–0.95; Fig. 3D; Supplementary Table S4).

Decrease in methylation levels after *HP* eradication. *HP* was eradicated at 50 weeks after infection, and the methylation levels of the 10 CGIs were measured in GECs of the gerbils before and 1, 10, and 20 weeks after the eradication (Fig. 3A). Complete absence of *HP* was confirmed by PCR of *HP* genomic DNA (Fig. 4C). At 1 week after eradication, no decrease in methylation was observed (Fig. 3B; Supplementary Fig. S3). At 10 weeks after eradication, in contrast, the methylation levels of the 10 CGIs decreased to 9% to 32% of those before the eradication (significant for 9 of the 10 CGIs, except for SH6). An additional 10 weeks (20 weeks after eradication) did not lead to a further decrease in methylation levels. Importantly, the methylation levels after the decrease due to eradication were still significantly ($P < 0.01$ for two CGIs, and $P < 0.05$ for seven CGIs) higher than those in gerbils without any *HP* infection in their life.

Close association between methylation induction and inflammation, and not *HP* itself. *HP* infection is known to induce severe inflammation in gastric mucosae in gerbils, as in humans. Histologic analysis revealed that infiltration of polymorphonuclear cells and mononuclear cells started at 5 to 10 weeks after *HP* infection, and it became severe at 50 weeks (Fig. 4A; Supplementary Fig. S4). After eradication, a decrease in infiltration was not clear at 1 week, but was marked by 10 and 20 weeks (Fig. 4A). These histologic findings were paralleled by expression of inflammatory cell markers [*Cd3g*, *Cd14*, *Ela2*, and *Ms4a1* (*Cd20*) for T cell, macrophage, neutrophil, and B cell, respectively] in gastric tissues containing both mucosal and submucosal layers (Fig. 4B). Although *Ms4a1* expression decreased after eradication, gerbils without eradication (continuous infection) also showed a similar decrease, indicating that the decrease in *Ms4a1* expression (B-cell infiltration) was independent of *HP* eradication.

To explore the components of inflammation associated with methylation induction, the expression of inflammation-related genes [*Cox2*, *Cxcl2* (*MIP-2*), *Ifng*, *Il1b*, *Il2*, *Il4*,




Figure 1. Isolation of CGIs that were aberrantly methylated in gerbil gastric cancers and GECs. A, a CpG map of the fragment isolated by MS-RDA. Vertical lines, individual CpG sites; arrows, positions of MSP primers; open arrows (HE6 and SA9), positions of bisulfite sequencing primers. B, representative results of MSP analyses in GECs from gerbils with and without *HP* infection for 50 wk and gastric cancer cell lines. M, MSP using a primer pair specific to methylated DNA; U, MSP using a primer pair specific to unmethylated DNA; M-control, genomic DNA treated with *SssI* methylase; U-control, DNA amplified with GenomiPhi.

Il6, *Il7*, *Nos2* (*iNos*), and *Tnf* (*Tnf- α*)] was also quantified (Fig. 4B). A marked increase after *HP* infection and a decrease after eradication were observed for *Cxcl2*, *Il1b*, *Nos2*, and *Tnf*, paralleling inflammatory cell markers (Fig. 4B). The *Cox2*, *Ifng*, *Il2*, *Il4*, and *Il6* expression did not parallel the methylation levels after *HP* eradication, and the *Il7* expression showed a paradoxical increase compared with the group of continuous infection (Fig. 4B). Regarding the amount of *HP* in gastric mucosae, it had no association with methylation levels (Fig. 4C).

There remained a possibility that inflammatory cells had methylation of the CGIs analyzed, and that their contamination into GECs led to an apparent increase in methylation

levels. To exclude this possibility, we analyzed the methylation levels of the 10 CGIs in DNA extracted from the whole blood of *HP*-infected gerbils. With the exception of SB1 and SB5, which showed relatively high methylation levels in the blood, 8 of the 10 CGIs showed almost no methylation (Supplementary Fig. S5). This excluded the possibility that methylation detected in the GECs was due to methylation in inflammatory cells contaminating the GECs.

Suppression of methylation induction by suppression of inflammation. To conclude that inflammation is indispensable for methylation induction, we suppressed *HP*-induced inflammation by administration of CsA, which blocks T-cell activation through inhibition of the calcineurin signal




Figure 2. Methylation of homologous regions in human gastric mucosae. A, methylation levels in human gastric mucosal biopsies. Left, genomic structures and the regions analyzed by qMSP. Vertical lines, individual CpG sites; gray box, regions with homology between gerbil and man; open boxes, exons; faced arrowheads, positions of primers for qMSP. Right, result of qMSP analyses. Methylation levels were quantified in 10 healthy volunteers without *HP* infection and 10 with *HP* infection. Bold horizontal bars, average. **, $P < 0.01$. B, methylation levels in primary gastric cancers. Fourteen primary gastric cancer samples and a pool of 10 mucosal biopsies of *HP*-infected healthy volunteers were analyzed. For the gastric mucosae, their mean methylation level and SD are shown. PMR, percentage of the methylated reference.




Figure 3. Temporal profiles of DNA methylation levels after *HP* infection and its eradication. **A**, experimental design for *HP* infection and eradication. The numbers of gerbils that were successfully eradicated of *HP* are indicated in parentheses. **B**, temporal profiles of methylation levels. Methylation levels are shown as mean + SD. †, $P < 0.05$, compared with noninfected gerbils; *, $P < 0.05$, compared with the methylation level before the eradication. **C**, the presence of dense methylation in the GECs of gerbils with *HP* infection. Bisulfite sequencing of HE6 and SA9 was done in GECs of a gerbil infected with *HP* for 50 wk and an age-matched control gerbil. The fractions of clones with dense methylation were in accordance with methylation levels (percentages of the methylated reference given in parentheses). Bars, CpG sites with which qMSP primers were designed. Similar patterns were observed for another pair of noninfected and infected gerbils (data not shown). **D**, scattered plot of methylation levels of HE6 versus those of SA9. The values of all 149 gerbils whose methylation was analyzed in this study were plotted. r , correlation coefficient.

(ref. 28; Fig. 5A). Macroscopically, administration of CsA to *HP*-infected gerbils markedly suppressed erosion and the formation of nodules. Histologically, it suppressed induction of hyperplasia almost completely, but infiltration of mononuclear and polymorphonuclear cells remained (Fig. 5B). Importantly, the number of *HP* colonized in the stomach was not affected by the CsA treatment (Supplementary Fig. S6). The expression levels of inflammatory cell markers (*Cd3g*, *Cd14*, and *Ela2*) were not reduced, indicating that the

number of inflammatory cells normalized against other cells was not affected. However, the expression of three inflammation-related genes (*Cxcl2*, *Il1b*, and *Nos2*), whose expression paralleled methylation induction in the temporal analysis, was significantly reduced by the CsA treatment (Fig. 5C).

The DNA methylation levels of the 10 CGIs were markedly reduced in GECs of CsA-treated gerbils (0% to 28% of methylation levels of GECs from *HP*-infected gerbil without the

CsA treatment; Fig. 5D; Supplementary Fig. S7). These results showed that the CsA treatment suppressed inflammatory responses but not *HP* colonization, and that the suppression of inflammatory responses markedly repressed methylation induction.

Expression analysis of genes with promoter methylation in *HP*-infected GECs. HG2, SC3, and SD2 were located in the

promoter regions of *Gpr37*, *Rnf152*, and *Nptx2*, respectively. Promoter CGIs are generally resistant to DNA methylation (29), and only when genes are transcribed at low levels are they susceptible to DNA methylation (30–32). To confirm the low expression and the effect of methylation on gene expression, we analyzed their expression levels in GECs isolated from gerbils with and without *HP* infection (10 and 50 weeks




Figure 4. Changes in inflammation after *HP* infection and its eradication. **A**, histologic changes in gastric mucosa before and after *HP* eradication. Sections were stained with hematoxylin, eosin, and Alcian blue. Infiltration of numerous mononuclear cells (arrowheads) and polymorphonuclear cells (arrows) did not change at 1 wk after eradication but markedly decreased at 10 and 20 wk. However, the presence of fibrosis and heterotopic proliferative glands (*) did not differ. **B**, temporal profiles of expression of inflammatory cell markers and inflammation-related genes. Red, green, and blue lines, gerbils with continued infection, gerbils with eradication, and those without any *HP* infection, respectively. **C**, numbers of *HP* in the gerbil stomach. Real-time PCR of *HP*-specific DNA using DNA extracted from gastric tissues containing mucus was done. Values are shown as mean \pm SD. †, $P < 0.05$, compared with noninfected gerbils; *, $P < 0.05$, compared with the expression level before eradication.




Figure 5. Suppression of inflammation and methylation induction by CsA treatment. **A**, experimental design for CsA treatment and *HP* infection. **B**, macroscopic (top) and histologic (bottom) analyses of gastric mucosae. Hyperplastic changes in pyloric area were prominent in *HP*-infected gerbils without the CsA treatment and were markedly suppressed by the CsA treatment. Infiltration of mononuclear cells (arrowheads) and polymorphonuclear cells (arrows) was also severe in *HP*-infected gerbils without the CsA treatment and was repressed in CsA-treated animals. Gastric mucosae of *HP*-negative gerbils with CsA treatment showed no abnormal changes (data not shown). **C**, expression of inflammatory cell markers and inflammation-related genes. The expression of inflammatory cell markers normalized to *Gapdh* expression was not reduced. However, the expression of three inflammation-related genes (*Cxcl2*, *Il1b*, and *Nos2*) was significantly reduced by the CsA treatment. **D**, methylation levels in GECs. The CsA treatment markedly suppressed methylation induction by *HP* infection. Bold horizontal bar, average. *, $P < 0.05$; **, $P < 0.01$.

after infection) and in gastric cancer cell lines. All the three genes showed low expression levels in the GECs of non-infected and infected gerbils (Supplementary Fig. S8). *Rnf152* expression was significantly decreased in *HP*-infected gerbils compared with noninfected gerbils (44% and 25% at 10 and 50 weeks, respectively, after infection; $P < 0.001$). None of the three genes were expressed in cancer cell lines with complete methylation of these CGIs (Fig. 1B; Supplementary Fig. S8, top).

The absence of DNA methyltransferase upregulation. DNA methyltransferases (Dnmt) are final effectors of maintenance and induction of DNA methylation, and their overexpression is frequently observed in various types of human cancers (33). To analyze possible upregulation of Dnmts by *HP* infection, expression levels of *Dnmt1*, *Dnmt3a*, and *Dnmt3b* mRNAs were quantified in GECs of gerbils with and without *HP* infection. Contrary to our initial expectation, the expression levels of the three Dnmts were significantly lower in GECs with *HP* infection (1/2 to 1/3) than those without (Supplementary Fig. S8, bottom).

Discussion

Our study using a gerbil model showed that *HP* infection is causally involved in induction of aberrant DNA methylation in GECs. Thus far, a strong association has been shown between the presence of *HP* infection and high methylation levels or high incidence of methylation in human gastric mucosae (5, 10–12). Taking advantage of an animal model, we were able to conduct an experiment by infecting gerbils with *HP* and showed that *HP* infection was the cause of methylation induction.

The critical role of inflammation in methylation induction was shown. Temporal analysis showed that methylation levels were closely associated with infiltration of inflammatory cells, and suppression of inflammation by CsA markedly repressed methylation induction even in the presence of *HP*. These results indicated that *HP* itself was not necessary for methylation induction once inflammation was induced by it. This finding is important because a direct role of *HP* is suggested by the facts that the SHP2 oncoprotein is deregulated by injection of virulent factors such as CagA into GECs (34) and *HP* possesses multiple DNA (cytosine-5) methyltransferases (35).

Among the inflammation-related genes analyzed, the expression levels of *Cxcl2*, *Il1b*, *Nos2*, and *Tnf* were upregulated in the stomach with *HP* infection and decreased after eradication, almost paralleling those of methylation levels. In the CsA treatment, in which methylation induction was markedly suppressed, upregulation of *Cxcl2*, *Il1b*, and *Nos2* by *HP* infection was significantly suppressed and that of *Tnf* also had a tendency to be suppressed. These results suggest that some specific inflammation-related genes are cooperatively involved in methylation induction by *HP* infection. In human ulcerative colitis and hepatitis (cirrhosis), where aberrant methylation is believed to be induced, increased expression of *IL8* (human functional homolog of *Cxcl2*), *IL1B*, *NOS2*, and *TNF* was also observed (36–39), suggesting that upregulation

of these genes is a common feature of methylation-associated inflammation. Especially for human *IL1B*, its allele with a specific single nucleotide polymorphism is known to be associated with increased gastric cancer risk and increased incidence of *CDH1* promoter methylation in gastric cancers (40, 41). Also, increased production of nitric oxide, due to upregulation of a nitric oxide synthase (*NOS2*) by *IL1B* or administration of nitric oxide donors, induced methylation of *FMRI* and *HPRT* genes *in vitro* (42).

This study also clearly shows that methylation in gastric mucosae with *HP* infection consists of temporary and permanent components, which has been suggested by studies in humans (5, 10). Methylation that disappeared after eradication corresponds to the temporary component, and methylation that did not disappear corresponds to the permanent component. A pyloric gland (mucosal epithelia) is known to be composed of one or a few stem cells, multiple progenitor cells, and a large number of differentiated cells, and it is renewed within 3 to 14 days (43, 44). Temporary methylation is likely to have been induced in progenitor or differentiated cells, which will finally drop off from the gastric epithelium. Permanent methylation is likely to be induced in stem cells, which will remain for life. In humans, methylation levels in gastric mucosae without *HP* infection correlate with gastric cancer risk (5, 10), and this fact is also in line with the hypothesis that permanent methylation in gastric mucosae without *HP* infection reflects methylation in stem cells.

HG2, SC3, and SD2 were methylated in GECs, although they were located in promoter CGIs, which are generally resistant to DNA methylation (29). Among promoter CGIs, those of genes with low transcription are known to be susceptible to methylation (30, 31, 45), and as expected, all the three genes had low transcription levels in GECs. Transcription levels at 10^{-4} to 10^{-3} /*Gapdh* (*GAPDH*) correspond to 1 to 10 copies of mRNA per cell and are less than 35% of the average expression level of all the genes analyzed by expression microarray (46). Because their methylation levels in GECs of gerbils infected with *HP* for 10 and 50 weeks were less than a few percent, their methylation was unlikely to have affected the overall expression levels in gastric mucosae. As a response to *HP* infection, *Rnf152* was downregulated whereas *Gpr37* and *Nptx2* were not.

Promoter CGIs of *GPR37* and *NPTX2* were highly methylated in human gastric mucosae with *HP* infection and were frequently methylated in human gastric cancers. Because their tumor-suppressive functions have not been reported and they are not expressed in normal gastric mucosae (RefExA database⁴), their silencing is unlikely to be causally involved in gastric carcinogenesis, and they are considered to be passengers. Likewise, methylated CGIs that were not associated with genes were likely to be passengers. However, it is now known that a lot of passengers and limited number of drivers are methylated to high and small degrees, respectively, in human gastric mucosae with *HP* infection (5, 45). Therefore, although most methylation identified here was

⁴ http://157.82.78.238/refexa/main_search.jsp

considered to be passenger, it is likely that tumor-suppressor genes are also methylated in association with their methylation. Gastric mucosa with accumulation of silencing of various genes, including both drivers and passengers, is considered to form a field where cancers will develop (epigenetic field for cancerization; refs. 7, 10, 47).

As a final effector of methylation induction, we examined overexpression of *Dnmts*, which are implicated in methylation induction in various human cancers (33). Unexpectedly, all the three *Dnmts* were downregulated by *HP* infection. Our recent data in humans also showed that mRNA levels of *Dnmts* had decreasing tendencies in *HP*-infected gastric mucosae (45). These results indicate that overexpression of *Dnmts* is not involved in *HP*-induced methylation induction, and suggest that local distribution of *Dnmts* and/or protective factors, such as the presence of RNA polymerase II (48), might be disturbed by inflammation.

Genome-wide screening to isolate DNA fragments methylated by *HP* infection was done by MS-RDA, which is applicable to any species without genome information. We used cell lines as the driver so that we could avoid heterogeneity of primary samples and aberrant methylation will be present in all the DNA molecules in the driver. This was considered to be essential for a genome-wide screening because most methods cannot detect small differences. Although cell lines might have artificial methylation, we confirmed the presence of specific methylation in GECs, and a high-sensitivity meth-

od, qMSP, was used for this. As expected, methylation levels of CGIs identified here were small (i.e., a few percent) in GECs with *HP* infection, showing that the strategy was correct.

In summary, *HP* infection was causally involved in induction of aberrant DNA methylation, and a critical role of inflammation in the induction was indicated. This model is expected to be useful in analyzing detailed molecular mechanisms for induction of aberrant DNA methylation.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

The authors are grateful to Dr. Takashi Sugimura for his critical discussion and sustained encouragement.

Grant Support

Grants-in-Aid for Cancer Research and for the Third-Term Comprehensive Cancer Control from the Ministry of Health, Labour, and Welfare, Japan.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 7/24/09; revised 11/10/09; accepted 11/27/09; published OnlineFirst 2/2/10.

References

- Jones PA, Baylin SB. The epigenomics of cancer. *Cell* 2007;128:683–92.
- Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. *Mol Cancer Res* 2006;4:221–33.
- Kondo Y, Kanai Y, Sakamoto M, Mizokami M, Ueda R, Hirohashi S. Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis—a comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. *Hepatology* 2000;32:970–9.
- Issa JP, Ahuja N, Toyota M, Bronner MP, Brentnall TA. Accelerated age-related CpG island methylation in ulcerative colitis. *Cancer Res* 2001;61:3573–7.
- Maekita T, Nakazawa K, Mihara M, et al. High levels of aberrant DNA methylation in *Helicobacter pylori*-infected gastric mucosae and its possible association with gastric cancer risk. *Clin Cancer Res* 2006;12:989–95.
- Toyota M, Itoh F, Kikuchi T, et al. DNA methylation changes in gastrointestinal disease. *J Gastroenterol* 2002;37 Suppl 14:97–101.
- Ushijima T. Epigenetic field for cancerization. *J Biochem Mol Biol* 2007;40:142–50.
- Moss SF, Blaser MJ. Mechanisms of disease: inflammation and the origins of cancer. *Nat Clin Pract Oncol* 2005;2:90–7.
- Uemura N, Okamoto S, Yamamoto S, et al. *Helicobacter pylori* infection and the development of gastric cancer. *N Engl J Med* 2001;345:784–9.
- Nakajima T, Maekita T, Oda I, et al. Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. *Cancer Epidemiol Biomarkers Prev* 2006;15:2317–21.
- Perri F, Cotugno R, Piepoli A, et al. Aberrant DNA methylation in non-neoplastic gastric mucosa of *H. pylori* infected patients and effect of eradication. *Am J Gastroenterol* 2007;102:1361–71.
- Kaise M, Yamasaki T, Yonezawa J, Miwa J, Ohta Y, Tajiri H. CpG island hypermethylation of tumor-suppressor genes in *H. pylori*-infected non-neoplastic gastric mucosa is linked with gastric cancer risk. *Helicobacter* 2008;13:35–41.
- Chan AO, Peng JZ, Lam SK, et al. Eradication of *Helicobacter pylori* infection reverses E-cadherin promoter hypermethylation. *Gut* 2006;55:463–8.
- Leung WK, Man EP, Yu J, et al. Effects of *Helicobacter pylori* eradication on methylation status of E-cadherin gene in noncancerous stomach. *Clin Cancer Res* 2006;12:3216–21.
- Tatematsu M, Tsukamoto T, Mizoshita T. Role of *Helicobacter pylori* in gastric carcinogenesis: the origin of gastric cancers and heterotopic proliferative glands in Mongolian gerbils. *Helicobacter* 2005;10:97–106.
- Nozaki K, Shimizu N, Ikehara Y, et al. Effect of early eradication on *Helicobacter pylori*-related gastric carcinogenesis in Mongolian gerbils. *Cancer Sci* 2003;94:235–9.
- Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of *Helicobacter pylori* on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomized controlled trial. *Lancet* 2008;372:392–7.
- Wong BC, Lam SK, Wong WM, et al. *Helicobacter pylori* eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. *JAMA* 2004;291:187–94.
- Nozaki K, Tanaka H, Ikehara Y, et al. *Helicobacter pylori*-dependent NF- κ B activation in newly established Mongolian gerbil gastric cancer cell lines. *Cancer Sci* 2005;96:170–5.
- Shimizu N, Ikehara Y, Inada K, et al. Eradication diminishes enhancing effects of *Helicobacter pylori* infection on glandular stomach carcinogenesis in Mongolian gerbils. *Cancer Res* 2000;60:1512–4.
- Cheng H, Bjerknes M, Amar J. Methods for the determination of epithelial cell kinetic parameters of human colonic epithelium isolated from surgical and biopsy specimens. *Gastroenterology* 1984;86:78–85.

22. Yamashita S, Takahashi S, McDonell N, et al. Methylation silencing of transforming growth factor- β receptor type II in rat prostate cancers. *Cancer Res* 2008;68:2112–21.
23. Ushijima T, Morimura K, Hosoya Y, et al. Establishment of methylation-sensitive-representational difference analysis and isolation of hypo- and hypermethylated genomic fragments in mouse liver tumors. *Proc Natl Acad Sci U S A* 1997;94:2284–9.
24. Kaneda A, Kaminishi M, Yanagihara K, Sugimura T, Ushijima T. Identification of silencing of nine genes in human gastric cancers. *Cancer Res* 2002;62:6645–50.
25. Niwa T, Yamashita S, Tsukamoto T, et al. Whole-genome analyses of loss of heterozygosity and methylation analysis of four tumor-suppressor genes in *N*-methyl-*N*'-nitro-*N*-nitrosoguanidine-induced rat stomach carcinomas. *Cancer Sci* 2005;96:409–13.
26. Kass DH, Kim J, Rao A, Deininger PL. Evolution of B2 repeats: the muroid explosion. *Genetica* 1997;99:1–13.
27. Weisenberger DJ, Campan M, Long TI, et al. Analysis of repetitive element DNA methylation by MethyLight. *Nucleic Acids Res* 2005;33:6823–36.
28. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. *Nature* 1992;357:695–7.
29. Ushijima T, Watanabe N, Okochi E, Kaneda A, Sugimura T, Miyamoto K. Fidelity of the methylation pattern and its variation in the genome. *Genome Res* 2003;13:868–74.
30. De Smet C, Loriot A, Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 5' region of gene MAGE-A1 in tumor cells. *Mol Cell Biol* 2004;24:4781–90.
31. Song JZ, Stirzaker C, Harrison J, Melki JR, Clark SJ. Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells. *Oncogene* 2002;21:1048–61.
32. Ushijima T, Okochi-Takada E. Aberrant methylations in cancer cells: where do they come from? *Cancer Sci* 2005;96:206–11.
33. Kanai Y, Hirohashi S. Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state. *Carcinogenesis* 2007;28:2434–42.
34. Hatakeyama M. Oncogenic mechanisms of the *Helicobacter pylori* CagA protein. *Nat Rev Cancer* 2004;4:688–94.
35. Vitkute J, Stankevicius K, Tamulaitiene G, et al. Specificities of eleven different DNA methyltransferases of *Helicobacter pylori* strain 26695. *J Bacteriol* 2001;183:443–50.
36. Cappello M, Keshav S, Prince C, Jewell DP, Gordon S. Detection of mRNAs for macrophage products in inflammatory bowel disease by *in situ* hybridisation. *Gut* 1992;33:1214–9.
37. Llorente L, Richaud-Patin Y, Alcocer-Castillejos N, et al. Cytokine gene expression in cirrhotic and non-cirrhotic human liver. *J Hepatol* 1996;24:555–63.
38. McLaughlan JM, Seth R, Vautier G, et al. Interleukin-8 and inducible nitric oxide synthase mRNA levels in inflammatory bowel disease at first presentation. *J Pathol* 1997;181:87–92.
39. Mihm S, Fayyazi A, Ramadori G. Hepatic expression of inducible nitric oxide synthase transcripts in chronic hepatitis C virus infection: relation to hepatic viral load and liver injury. *Hepatology* 1997;26:451–8.
40. El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. *Nature* 2000;404:398–402.
41. Chan AO, Chu KM, Huang C, et al. Association between *Helicobacter pylori* infection and interleukin 1 β polymorphism predispose to CpG island methylation in gastric cancer. *Gut* 2007;56:595–7.
42. Hmadcha A, Bedoya FJ, Sobrino F, Pintado E. Methylation-dependent gene silencing induced by interleukin 1 β via nitric oxide production. *J Exp Med* 1999;190:1595–604.
43. Hattori T, Fujita S. Tritiated thymidine autoradiographic study of cell migration and renewal in the pyloric mucosa of golden hamsters. *Cell Tissue Res* 1976;175:49–57.
44. Lee ER. Dynamic histology of the antral epithelium in the mouse stomach: III. Ultrastructure and renewal of pit cells. *Am J Anat* 1985;172:225–40.
45. Nakajima T, Yamashita S, Maekita T, Niwa T, Nakazawa K, Ushijima T. The presence of a methylation fingerprint of *Helicobacter pylori* infection in human gastric mucosae. *Int J Cancer* 2009;124:905–10.
46. Moriguchi K, Yamashita S, Tsujino Y, Tatematsu M, Ushijima T. Larger numbers of silenced genes in cancer cell lines with increased *de novo* methylation of scattered CpG sites. *Cancer Lett* 2007;249:178–87.
47. Nakajima T, Oda I, Gotoda T, et al. Metachronous gastric cancers after endoscopic resection: how effective is annual endoscopic surveillance? *Gastric Cancer* 2006;9:93–8.
48. Takeshima H, Yamashita S, Shimazu T, Niwa T, Ushijima T. The presence of RNA polymerase II, active or stalled, predicts epigenetic fate of promoter CpG islands. *Genome Res* 2009;19:1974–82.

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

Inflammatory Processes Triggered by *Helicobacter pylori* Infection Cause Aberrant DNA Methylation in Gastric Epithelial Cells

Tohru Niwa, Tetsuya Tsukamoto, Takeshi Toyoda, et al.

Cancer Res 2010;70:1430-1440. Published OnlineFirst February 2, 2010.

Updated version Access the most recent version of this article at:
doi:[10.1158/0008-5472.CAN-09-2755](https://doi.org/10.1158/0008-5472.CAN-09-2755)

Supplementary Material Access the most recent supplemental material at:
<http://cancerres.aacrjournals.org/content/suppl/2010/02/01/0008-5472.CAN-09-2755.DC1>

Cited articles This article cites 48 articles, 19 of which you can access for free at:
<http://cancerres.aacrjournals.org/content/70/4/1430.full.html#ref-list-1>

Citing articles This article has been cited by 35 HighWire-hosted articles. Access the articles at:
[/content/70/4/1430.full.html#related-urls](http://cancerres.aacrjournals.org/content/70/4/1430.full.html#related-urls)

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.